Modality
Fusion Protein
MOA
BiTE
Target
GLP-1R
Pathway
PI3K/AKT
WMGBMCholangiocarcinoma
Development Pipeline
Preclinical
~Mar 2018
→ ~Jun 2019
Phase 1
Sep 2019
→ Dec 2029
Phase 1Current
NCT05957675
175 pts·Cholangiocarcinoma
2019-09→2029-12·Completed
175 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-12-123.7y awayInterim· Cholangiocarcinoma
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1
Complet…
Catalysts
Interim
2029-12-12 · 3.7y away
Cholangiocarcinoma
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05957675 | Phase 1 | Cholangiocarcinoma | Completed | 175 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R |